NASDAQ · POCI
Precision Optics Corporation, Inc.
$4.59+$0.25 (+5.76%)
Precision Optics Corporation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.37% below the high.
Loading market information…
NASDAQ · PRPO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Precipio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Precipio, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$2.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Precipio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 27, 2025 | -$0.23-131.08% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.42-205.0% vs estimate | $5.21M-28.59% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.59+$0.25 (+5.76%)
Precision Optics Corporation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.37% below the high.
$9.81-$0.07 (-0.71%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.63% below the high.
$0.32-$0.00 (-0.54%)
Milestone Scientific Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.69% below the high.
$0.51$0.00 (0.0%)
Longduoduo Company Limited’s quoted price sits in the lower half of its reported 52-week range, 45.4% below the high.
$1.72-$0.19 (-9.95%)
Modular Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.79% below the high.
$1.20-$0.03 (-2.44%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.36% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
$3.21+$0.14 (+4.56%)
Apimeds Pharmaceuticals US, Inc’s quoted price sits in the lower half of its reported 52-week range, 94.62% below the high.
